MUFG Securities EMEA plc bought a new position in shares of Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 243,400 shares of the software maker’s stock, valued at approximately $2,346,000. MUFG Securities EMEA plc owned 0.14% of Allscripts Healthcare Solutions at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Meeder Asset Management Inc. increased its holdings in Allscripts Healthcare Solutions by 539.1% in the 4th quarter. Meeder Asset Management Inc. now owns 3,368 shares of the software maker’s stock worth $32,000 after acquiring an additional 2,841 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in Allscripts Healthcare Solutions by 864.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 684,189 shares of the software maker’s stock valued at $71,000 after buying an additional 613,215 shares in the last quarter. ETF Managers Group LLC grew its holdings in Allscripts Healthcare Solutions by 15.8% during the 4th quarter. ETF Managers Group LLC now owns 10,561 shares of the software maker’s stock valued at $102,000 after buying an additional 1,440 shares in the last quarter. Magnus Financial Group LLC purchased a new position in Allscripts Healthcare Solutions during the 4th quarter valued at about $111,000. Finally, QS Investors LLC grew its holdings in Allscripts Healthcare Solutions by 5,105.5% during the 4th quarter. QS Investors LLC now owns 12,337 shares of the software maker’s stock valued at $119,000 after buying an additional 12,100 shares in the last quarter.
A number of research analysts have weighed in on the company. Zacks Investment Research raised Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a report on Monday, January 21st. Citigroup lowered Allscripts Healthcare Solutions from a “buy” rating to a “neutral” rating and reduced their target price for the company from $14.00 to $12.00 in a report on Friday, February 22nd. BidaskClub raised Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. Finally, ValuEngine raised Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a report on Wednesday, January 9th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company. Allscripts Healthcare Solutions presently has an average rating of “Hold” and a consensus price target of $14.35.
Allscripts Healthcare Solutions (NASDAQ:MDRX) last issued its quarterly earnings data on Thursday, February 21st. The software maker reported $0.20 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by ($0.01). Allscripts Healthcare Solutions had a return on equity of 7.74% and a net margin of 18.15%. The business had revenue of $538.00 million for the quarter, compared to analysts’ expectations of $565.52 million. During the same period in the previous year, the firm posted $0.18 EPS. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, analysts predict that Allscripts Healthcare Solutions Inc will post 0.5 earnings per share for the current year.
About Allscripts Healthcare Solutions
Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.
Recommended Story: Penny Stocks, What You Need To Know
Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.